Want to see VTVT full AI Analyst Report?
Total Valuation
vTv Therapeutics has a market cap or net worth of $139.44M. The enterprise value is -$9.31M.
Market Cap$139.44M
Enterprise Value-$9.31M
Share Statistics
vTv Therapeutics has 3,938,654 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,938,654
Owned by Insiders11.52%
Owned by Institutions19.44%
Financial Efficiency
vTv Therapeutics’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -39.41%.
Return on Equity (ROE)-0.42
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-39.41%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-1.35M
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of vTv Therapeutics is 1770.0. vTv Therapeutics’s PEG ratio is 0.00.
PE Ratio1770.0
PS Ratio0.00
PB Ratio5.23
Price to Fair Value5.23
Price to FCF-13.34
Price to Operating Cash Flow-28.63
PEG Ratio0.00
Income Statement
In the last 12 months, vTv Therapeutics had revenue of 0.00 and earned -26.97M in profits. Earnings per share was -3.20.
Revenue0.00
Gross Profit0.00
Operating Income-32.81M
Pretax Income-31.08M
Net Income-26.97M
EBITDA-31.06M
Earnings Per Share (EPS)-3.20
Cash Flow
In the last 12 months, operating cash flow was -10.41M and capital expenditures 0.00, giving a free cash flow of -10.41M billion.
Operating Cash Flow-10.41M
Free Cash Flow-10.41M
Free Cash Flow per Share-2.64
Dividends & Yields
vTv Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.63
52-Week Price Change134.90%
50-Day Moving Average33.68
200-Day Moving Average32.27
Relative Strength Index (RSI)52.76
Average Volume (3m)5.07K
Important Dates
vTv Therapeutics upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
vTv Therapeutics as a current ratio of 13.54, with Debt / Equity ratio of 0.00%
Current Ratio13.54
Quick Ratio13.54
Debt to Market Cap0.00
Net Debt to EBITDA2.86
Interest Coverage Ratio-5.47K
Taxes
In the past 12 months, vTv Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
vTv Therapeutics EV to EBITDA ratio is -7.98, with an EV/FCF ratio of -9.82.
EV to Sales0.00
EV to EBITDA-7.98
EV to Free Cash Flow-9.82
EV to Operating Cash Flow-9.82
Balance Sheet
vTv Therapeutics has $98.09M in cash and marketable securities with $0.00 in debt, giving a net cash position of $98.09M billion.
Cash & Marketable Securities$98.09M
Total Debt$0.00
Net Cash$98.09M
Net Cash Per Share$24.90
Tangible Book Value Per Share$7.65
Margins
Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for vTv Therapeutics is $56.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$56.83
Price Target Upside49.09% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast216600.00%
EPS Growth Forecast79.14%